Details of the Drug Combination

General Information of Drug Combination (ID: DCFDCI3)

• Drug Combination Name: Hepzato + Topetecan
• Indication: Anaplastic large cell lymphoma; Status: Investigative [1]
• Component Drugs:
  Hepzato (DM2AZPP): N.A.
  Topetecan (DMAE6LK): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: SR
  Zero Interaction Potency (ZIP) Score: 3.23
  Bliss Independence Score: 3.98
  Loewe Additivity Score: 0.35
  LHighest Single Agent (HSA) Score: 3.93

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Hepzato

Disease Entry	ICD 11	Status	REF
Uveal Melanoma	2D0Y	Phase 3	[2]

Indication(s) of Topetecan

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Approved	[3]

Topetecan Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[4]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
• [3] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
• [4] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).